Integrase

Inhibitory Selectivity
Catalog No.Inhibitor Name Integrase
A10775Raltegravir (MK-0518)
*
A10347Elvitegravir (GS-9137, JTK-303)
****
A11068Dolutegravir (GSK1349572)
***
A10156BMS-707035
**
A11135MK-2048
***
A16014Cabotegravir (GSK744, GSK1265744)

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



9 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A10775 SALE

Raltegravir (MK-0518)

HIV-1 integrase inhibitor
Raltegravir (MK-0518) targets integrase, an HIV enzyme that integrates the viral genetic material into human chromosomes, a critical step in the pathogenesis of HIV.
A11068 SALE

S/GSK1349572 (Dolutegravir)

HIV integrase inhibitor
S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones.
A11135

MK-2048

HIV integrase inhibitor
MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.
A10156

BMS-707035

HIV-1 integrase inhibitor

BMS-707035 is an HIV-1 integrase (IN) inhibitor. HIV-1 integrase (IN) represents a therapeutically advantageous viral target to treat HIV/AIDS in the clinic.

A10347 SALE

Elvitegravir (GS-9137)

HIV integrase inhibitor
Elvitegravir (GS-9137) is a potent inhibitor of the strand-transfer step of integration mediated by human immunodeficiency virus type 1 (HIV-1) integrase.
A13984

GSK1265744 (GSK744) Sodium salt

HIV Integrase Inhibitor
GSK1265744 (GSK744) is a potential inhibitor of HIV integrase with IC50 value of 3 nM
A16014

GSK744 (S/GSK1265744)

HIV integrase inhibitor
GSK744 is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.
A16018

BI 224436

HIV integrase inhibitor
BI 224436 is a novel HIV-1 non-catalytic-site integrase inhibitor; has antiviral EC50s of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of >90 μM.
A16162

Dolutegravir Sodium

HIV integrase inhibitor
Dolutegravir sodium is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

9 Item(s)

per page

Set Descending Direction